Seventh Circuit urged to review AbbVie antitrust ruling

Twenty US states, the US Federal Trade Commission (FTC), and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

EC fines Teva €60.5m over pay-for-delay deal

27 November 2020 The European Commission has fined Teva and its subsidiary Cephalon €60.5 million for agreeing to delay a cheaper generic version of sleep disorder drug modafinil.

Americas

FTC’s $448m AbbVie win overturned

2 October 2020 A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.

Americas

US FTC settles pay-for-delay case with AbbVie

1 March 2019 The US Federal Trade Commission concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Seventh Circuit urged to review AbbVie antitrust ruling

More on this story

Editor's picks

Editor's picks

More features